Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 460 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type 2 Diabetic Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Purple Rice on Glucose Tolerance, Serum Lipids and Inflammation

NCT01720511
View directory record Official record
Conditions
Type 2 Diabetic
Interventions
Purple Rice, Brown Rice
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 23, 2026, 2:51 PM EDT
Recruiting Phase 4 Interventional

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

NCT05390892
View directory record Official record
Conditions
Type2Diabetes, ASCVD
Interventions
SGLT2 inhibitor, GLP-1 receptor agonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
36
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 1 Interventional Results available

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

NCT00886821
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CVX-096
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Miami Gardens, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 23, 2026, 2:51 PM EDT
Active, not recruiting No phase listed Observational

Prospective Decision Impact Trial of KidneyIntelX

NCT04960514
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
Interventions
KidneyIntelX
Diagnostic Test
Lead sponsor
Renalytix AI, Inc.
Industry
Eligibility
23 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Not yet recruiting Not applicable Interventional

Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction

NCT07165327
View directory record Official record
Conditions
Gestatiaonl Diabetes Mellitus, Pregnancy, Diabetes in Pregnancy, Insulin Dependent Diabetes Mellitus, Insulin
Interventions
Injection Port for Insulin Administration, Single-Use Insulin Needles
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 23, 2026, 2:51 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema

NCT02229175
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
bevacizumab, PASCAL Endpoint Management (EpM) laser treatment
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Not applicable Interventional Results available

AT GOAL: Adopting Technology for Glucose Optimization and Lifestyle in Pregnancy

NCT05370612
View directory record Official record
Conditions
Type2Diabetes, Pregnancy in Diabetic
Interventions
Dexcom G6 CGM, Participant Finger Stick Glucose Monitoring
Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 23, 2026, 2:51 PM EDT
Completed No phase listed Observational

SGLT2 Inhibition in Diabetes and Heart Failure

NCT02862067
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Heart Failure, Systolic
Interventions
Assessment of cardiorespiratory fitness
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 23, 2026, 2:51 PM EDT
Withdrawn No phase listed Observational

Differential Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds

NCT02347709
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Neuropathy, Type 2 Diabetes
Interventions
Diabetic Foot Ulcer Biopsy, Survey, Comprehensive Neuropathy Assessment, Wound Photography
Procedure · Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 23, 2026, 2:51 PM EDT
Completed No phase listed Observational

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics

NCT00960765
View directory record Official record
Conditions
Obesity, Morbid, Diabetes Mellitus, Type 2, Gastric Bypass
Interventions
Not listed
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 23, 2026, 2:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

NCT01900834
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
14 Years to 40 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Sep 23, 2026, 2:51 PM EDT
Terminated Not applicable Interventional

Efficacy of Near Infrared Phototherapy in Type 2 Diabetic Neuropathy

NCT02798393
View directory record Official record
Conditions
Neuropathy
Interventions
Infrared Phototherapy, Sham
Other
Lead sponsor
Healthlight, LLC
Industry
Eligibility
25 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Topeka, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes

NCT04880291
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases
Interventions
GFB-024, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

NCT00773279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
FlexTouch®, FlexPen®
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
65
States / cities
Burlingame, California • Concord, California • Encino, California + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional

WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

NCT00147758
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam hydrochloride
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
45
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

NCT01394055
View directory record Official record
Conditions
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 2Phase 3 Interventional

Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics

NCT01324921
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
No breakfast/beverage only, Breakfast, 10004RF
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Glen Ellyn, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 4 Interventional

A Study of Mouth Rinses in Type 1 and Type 2 Diabetic Participants

NCT04449952
View directory record Official record
Conditions
Gingivits in Diabetics
Interventions
Listerine Cool Mint, 5% Hydroalcohol Mouth Rinse, Colgate Cavity Protection Toothpaste, Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula, Concept Curve Winter Series Toothbrush, Listerine Cool Mint Floss
Other · Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

NCT00622284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
23
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

NCT00811889
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
Interventions
Placebo, Bardoxolone Methyl (RTA 402)
Other · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Montgomery, Alabama • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

NCT00542009
View directory record Official record
Conditions
Weight Management, Treatment Of Obesity
Interventions
CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD, Placebo, CE-326,597 5mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • National City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

NCT02739984
View directory record Official record
Conditions
Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
Interventions
Evolocumab, Placebo to Evolocumab
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
46
States / cities
Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 23, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 23, 2026, 2:51 PM EDT